Active Ingredient History
Berzosertib is a drug originally invented by Vertex Pharmaceuticals and licensed to Merck KGaA, Darmstadt, Germany, for development. It acts as a potent inhibitor of the enzyme ataxia telangiectasia and Rad3 related (ATR) and with lower potency as an inhibitor of ATM serine/threonine kinase (ATM). These enzymes are both involved in detecting DNA damage as part of cell cycle checkpoints during cell division. By inhibiting their activity, berzosertib interferes with the ability of rapidly dividing cells to detect damage to DNA, and this makes it useful as a potential treatment for some forms of cancer by causing accumulation of DNA damage in the cancer cells and thus reducing their viability. It has progressed furthest in trials for the treatment of ovarian cancer, though also shows activity against numerous other cancer types. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Brain Neoplasms (Phase 1)
Breast Neoplasms (Phase 1)
Carcinoma, Neuroendocrine (Phase 1/Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)
Carcinoma, Ovarian Epithelial (Phase 1/Phase 2)
Carcinoma, Squamous Cell (Phase 1)
Carcinoma, Transitional Cell (Phase 2)
Colorectal Neoplasms (Phase 1)
Esophageal Neoplasms (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Hamartoma (Phase 2)
Leiomyosarcoma (Phase 2)
Lung Neoplasms (Phase 1/Phase 2)
Neoplasms (Phase 1/Phase 2)
Neuroendocrine Tumors (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 1)
Prostatic Neoplasms (Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 1)
Stomach Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 1/Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue